J. Prljic

发表

New in silico and conventional in vitro approaches to advance HIV drug discovery and design

E. Crespan, G. Maga, N. Veljkovic, 2013, Expert opinion on drug discovery.

Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b

N. Veljkovic, S. Glišić, V. Perovic, 2012, The Protein Journal.

Lipoprotein lipase: A bioinformatics criterion for assessment of mutations as a risk factor for cardiovascular disease

N. Veljkovic, S. Glišić, P. Arrigo, 2008, Proteins.

Discovery of new therapeutic targets by the informational spectrum method.

M. Botta, N. Veljkovic, S. Glišić, 2008, Current protein & peptide science.

AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy.

N. Veljkovic, V. Veljkovic, S. Müller, 2001, Vaccine.

EMILINs interact with anthrax protective antigen and inhibit toxin action in vitro.

N. Veljkovic, G. Ligresti, A. Colombatti, 2008, Matrix biology : journal of the International Society for Matrix Biology.

Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors

N. Veljkovic, S. Glišić, V. Perovic, 2019, Front. Cell. Infect. Microbiol..

Localization of recognition site between transforming growth factor-β1 (TGF-β1) and TGFβ receptor type II: possible implications in breast cancer

V. Veljkovic, N. Todorović-Raković, D. Nikolić-Vukosavljević, 2004 .

Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease.

S. Pongor, K. Vlahovicek, N. Veljkovic, 2003, The journal of peptide research : official journal of the American Peptide Society.

Study of apoB gene signal peptide insertion/deletion polymorphism in a healthy Serbian population: no association with serum lipid levels.

S. Glišić, D. Alavantic, N. Radovanović, 1997, Clinica chimica acta; international journal of clinical chemistry.

Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic

M. Scotch, N. Veljkovic, S. Glišić, 2015, Front. Microbiol..

RECOMBINATION PROPERTY OF THE HIV-1 gp120 GENE

N. Veljkovic, V. Veljkovic, J. Prljic, 2004, International reviews of immunology.

SAFETY AND ETHICAL CONSIDERATION OF AIDS VACCINE

V. Veljkovic, J. Prljic, T. Veljkovic, 2004, International reviews of immunology.

A bioinformatics approach to identify natural autoantibodies from healthy blood donors' sera reactive with the HCV NS5A-derived peptide by immunoassay.

N. Veljkovic, S. Glišić, Xuezhong Ma, 2011, Viral immunology.

Inhibition of SARS-CoV-2 Mpro with Vitamin C, L-Arginine and a Vitamin C/L-Arginine Combination.

S. Glišić, R. Prodanović, Milan Senćanski, 2023, Frontiers in bioscience.

Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease.

R. Manfredi, N. Veljkovic, W. Stringer, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Simple and general criterion for "in silico" screening of candidate HIV drugs.

N. Veljkovic, S. Glišić, V. Perovic, 2013, Current pharmaceutical biotechnology.

Improving attrition rates in Ebola virus drug discovery

N. Veljkovic, S. Glišić, V. Perovic, 2015, Expert opinion on drug discovery.